Werewolf Therapeutics: Preliminary Data From Phase 1 Clinical Trial of WTX-330 Expected in the 2Q of 2024 >HOWL
Werewolf Therapeutics: Preliminary Data From Phase 1 Clinical Trial of WTX-330 Expected in the 2Q of 2024 >HOWL
Werewolf Therapeutics：WTX-330 的 1 期臨床試驗的初步數據預計在 2024 年第二季度發佈 >HOWL
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊